Nmp

Quick links to important sections

Nmp

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nmp

What is Nmp? (Natural Micronised Progesterone)

Property Description
Active ingredient Progesterone
Form Micronised soft-gel capsules, suppositories
Pharmacological class Progestogen, Steroidal HRT agent
General purpose Hormonal balance and support
Origin Natural, Bio-identical

What Type of Medicine is Natural Micronised Progesterone (Nmp)?

Natural Micronised Progesterone (Nmp) is a steroidal hormone medicine whose active ingredient, Progesterone, is chemically identical to the endogenous hormone naturally produced in the human body. This drug is classified as a progestogen, which is an agent that activates progesterone receptors, and it functions as a Hormone Replacement Therapy (HRT) agent.

This medicine is frequently termed bio-identical, a designation supported by pharmacological studies confirming its structural match to native progesterone. This feature often influences its use in hormone substitution protocols compared to chemically modified synthetic progestins.

Nmp Composition: Natural, Bio-Identical, and Micronised

The core of the medicine is its natural origin and bio-identical composition. The substance is characterized by its micronised formulation, a specialized manufacturing process where the Progesterone powder is milled into fine particles. This micronisation is critically important, as it enhances the drug's solubility and bioavailability, enabling effective absorption.

Nmp is typically supplied in soft-gel capsules for oral delivery or in vaginal suppositories, often suspended in an inert lipid vehicle. The choice of the micronised form is driven by the need for reliable systemic absorption following administration.

General Purpose of Progestogen Therapy

The overarching purpose of Nmp therapy is to support and stabilize the physiological environment by restoring and maintaining hormonal balance. It acts to regulate and counteract the effects of estrogen, a function clinically recognized for supporting various cyclic and reproductive processes.

The drug achieves this by activating progesterone receptors to promote the maturation and stability of the uterine endometrium, thereby supporting essential gonadal hormone health.

What side effects are possible with Nmp?

Possible Side Effects and Safety Information

The safety profile of Natural Micronised Progesterone (Nmp) is defined by regulatory documents based on clinical trial data and post-marketing surveillance, detailing adverse effects classified by frequency and system involvement.


Officially Classified Adverse Reactions

Adverse reactions are formally categorized based on incidence rates observed in clinical studies and documented in official prescribing information:

Frequency Category Associated Adverse Reactions (Examples)
Very Common (ge 1/10) Headache, Abdominal pain, Breast tenderness, Emotional lability
Common (ge 1/100 to < 1/10) Dizziness, Abdominal bloating, Nausea/Vomiting, Fatigue, Nervousness
Uncommon (ge 1/1,000 to < 1/100) Acne, Pruritus (itching), Mood alteration

Effects are typically grouped into System-Organ-Classes such as Nervous System Disorders, Gastrointestinal Disorders, and Reproductive System and Breast Disorders.


Serious Adverse Reactions and Safety Constraints

The regulatory label identifies specific Serious Adverse Reactions, particularly when Nmp is used in combination with estrogen as Hormone Replacement Therapy (HRT). These risks include Venous Thromboembolism (VTE) (such as Deep Vein Thrombosis and Pulmonary Embolism), Arterial Thromboembolism (such as Stroke), and an increased risk of Breast Cancer with long-term combined use.

Safety-related restrictions define situations where the medicine is generally contraindicated, including active thromboembolic disorders, severe liver disease, and known or suspected hormone-sensitive malignancy. The label notes that certain non-serious effects, such as dizziness or spotting, may be more common at the start of treatment, while some serious risks are associated with long-term exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose information for Natural Micronised Progesterone (Nmp) is based strictly on descriptions documented in official regulatory labeling. Symptoms associated with overexposure involve effects on the central nervous system and the gastrointestinal system.

Documented Overdose Manifestations
Symptoms may include somnolence (sleepiness), dizziness, nausea and vomiting.
Other signs listed are euphoria, depressive mood, tiredness (fatigue), acne, hairiness (hirsutism), and dysmenorrhoea (painful periods).

Immediate Actions Required

Regulatory authorities mandate seeking medical help immediately upon suspected overexposure. When an overdose is thought to have occurred, an individual is required to contact a poison control center or seek immediate medical attention. This emergency action is necessary even if severe symptoms are not yet apparent.

Official Overdose Management

Treatment for Nmp overdose, as outlined in official documents, involves the discontinuation of progesterone. The required procedural management is the institution of appropriate symptomatic and supportive care. The regulatory profile states that no specific antidote is known, meaning management focuses exclusively on treating the documented manifestations as they occur. No explicit population-specific considerations or serious life-threatening outcomes are documented as direct acute manifestations of overdose in the labeling.

Therapeutic Uses of Nmp

Main Uses and Benefits of Natural Micronised Progesterone (Nmp)

Natural Micronised Progesterone (Nmp) is commonly used to help manage the symptoms related to systemic imbalance and conditions characterized by periods of heightened symptoms, primarily in the domains of menopausal health and reproductive support.


Supporting Menopausal Comfort and Uterine Health

Nmp is commonly used along with estrogen therapy to manage symptoms of menopause. This application is commonly used to help with symptom clusters that may become intense or disruptive, such as hot flashes and night sweats, which may interfere with daily functioning and sleep.

In women undergoing Hormone Replacement Therapy (HRT) who still have an intact uterus, Nmp may be part of symptomatic management applied to help maintain the functional stability of the uterine lining, offering a key supportive benefit.


Reproductive Health and Stabilization of Cycles

The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns related to hormonal insufficiency. This includes managing conditions such as the absence of menses (secondary amenorrhea), irregular bleeding patterns, and providing supportive luteal phase support during treatments like In-Vitro Fertilization (IVF). This assistance contributes to easing symptoms associated with episodic or fluctuating manifestations.


Quick Fact: Relief for Symptom Clusters

Nmp is considered relevant for easing symptom clusters including hormone-related mood swings, heightened anxiety, and overall irritability, which interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Natural Micronised Progesterone

Regulatory agencies define specific population criteria that determine eligibility for Natural Micronised Progesterone (Nmp). The medicine is primarily approved for adult women for conditions like secondary amenorrhea and as a component of Hormone Replacement Therapy (HRT) in women with an intact uterus. Specific contraindications strictly prohibit its use.

Classification Eligibility Rule (Official Documentation)
Absolute Contraindications History of or active thromboembolic disorders (DVT, PE, stroke), known or suspected breast cancer or other hormone-dependent malignancies, acute liver disease, and undiagnosed vaginal bleeding. Contraindication is also specified for patients with known hypersensitivity to progesterone or excipients like peanut oil or soybean lecithin.
Age-Related Rules Not indicated in the pediatric population as safety and efficacy are not established. Women 65 years and older on combination HRT may face an increased risk of probable dementia.
Restricted Use Use requires caution and supervision in patients with conditions such as hypertension, diabetes mellitus, epilepsy, migraine, and renal impairment.
Reproductive Status Use is contraindicated for HRT during pregnancy and is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding drug-drug, drug-food, or drug-substance interactions for a medicinal product specifically named Nmp is not consistently available in the major governmental drug labeling databases (e.g., those maintained by the FDA or EMA). The term 'Nmp' is often used as an abbreviation for chemical compounds or regulatory policy concepts rather than an active pharmaceutical ingredient with an approved, documented interaction profile.

Official Interaction Profile Summary

Interaction Scope Regulatory Status
Specific Interacting Medicines None explicitly listed in official drug labeling found.
Interacting Product Classes None explicitly listed in official drug labeling found.
Mechanistic Basis No official, product-specific mechanism (e.g., CYP enzyme inhibition/induction) identified.
Timing or Spacing Rules No specific timing or administration requirements documented.
Official Classification No high-level classification (e.g., 'Contraindicated,' 'Serious,' 'Monitor Closely') is available.

In the absence of a defined regulatory statement, patients and healthcare providers must consult updated clinical and pharmacology resources before co-administering any other prescription drugs, over-the-counter medicines, or dietary supplements with this product. Always ensure that the prescribing professional is aware of the patient's complete and current medication history to avoid potential unknown interactions.

Mechanism of Action

How Nmp Works: Mechanism of Action

Nmp exerts a dual pharmacodynamic effect across central and peripheral systems. In the central nervous system, specific peptides derived from Nmp act as agonists on NMDA receptors. This molecular interaction enhances neuronal ion flow, thereby modulating glutamatergic signaling and influencing processes related to neuronal signal transduction and subsequent gene transcription.

Separately, Nmp engages a critical transcriptional mechanism by acting as an activator of the KLF2 transcription factor, primarily within the peripheral vascular endothelium. This activation supports the genetic expression of factors associated with the attenuation of inflammatory pathways and the direct modulation of endothelial cell activity. The combined action defines the full scope of Nmp's mechanistic influence, spanning both the central neuronal pathways and the peripheral regulatory systems.

Dosage and Administration Information

How Natural Micronised Progesterone (Nmp) is Used

The usage of Natural Micronised Progesterone is governed by specific instructions concerning the route, schedule, and duration of administration as detailed in regulatory documents.


Administration Route and Forms

Nmp is administered via two primary, officially approved routes: the oral route using soft-gel capsules or the vaginal route using specific capsules or inserts. The choice of route is directly tied to the specific use pattern; for example, vaginal administration is required for applications such as Luteal Phase Support in Assisted Reproductive Technology.

Official Dosing Schedule

The schedule follows either a sequential (cyclic) pattern or a continuous daily pattern. For use as an adjunct to estrogen therapy, 200 mg is typically prescribed once daily for 12 sequential days per 28-day cycle. In contrast, for regimens requiring higher doses, such as Luteal Phase Support, 600 mg per day is administered in divided doses via the vaginal route. The duration of use is also regimen-specific, ranging from short 10-day courses to extended use continuing up to 10 to 12 weeks of pregnancy.

Contextual Use Instructions

Oral capsules are consistently specified to be taken at bedtime. Official guidance advises taking the capsule with a glass of water while standing to facilitate swallowing. Should a dose be missed, regulatory instruction advises against doubling the next dose and recommends skipping the missed dose if it is almost time for the next scheduled administration. No specific dose adjustments are noted for older adults in the context of HRT.

Recent Clinical Evidence

Research evidence / Overview of studies for Nmp

Evidence for Uterine Lining Protection During Estrogen Therapy

Research has primarily focused on Natural Micronised Progesterone (Nmp) use alongside estrogen therapy in postmenopausal women who still have a uterus. This research explores how Nmp affects the structural change in the uterine lining when estrogen is also being used. Studies have employed long-term observational cohort studies and Systematic Reviews to examine outcomes primarily focused on monitoring the incidence of abnormal cell growth in the uterus, known as Endometrial Hyperplasia, and the development of Endometrial Cancer.

Studies reported patterns of endometrial hyperplasia and cancer incidence when comparing women using Nmp with estrogen versus those using estrogen alone. Research also explored the relationship between various hormone regimens and observed differences in unscheduled bleeding patterns.


️ Evidence for Menopause-Related Vasomotor Symptoms (Hot Flashes and Night Sweats)

Nmp was evaluated in research exploring how symptoms change over time, specifically focusing on vasomotor symptoms such as hot flashes and night sweats. The majority of data come from short-term Randomized Controlled Trials (RCTs) where participants were monitored closely. Researchers in these studies focused on standardized scoring scales to measure the frequency and severity of the symptoms, and also measured sleep quality.

Studies report how symptoms evolved in the observed populations, with some trials observing changes in VMS frequency and severity scores over periods typically lasting 12 weeks to 6 months. However, findings were mixed across studies, and some reports described a substantial rate of perceived change also measured in the placebo groups.


Evidence for Luteal Phase Support in Assisted Reproduction

Research was studied for Nmp's application as Luteal Phase Support (LPS) for women undergoing assisted reproductive technology (ART) treatments. The evidence base is supported by Meta-analyses and a number of Randomized Controlled Trials (RCTs). These studies research examined reproductive endpoints, with primary outcomes focused on Live Birth Rate (LBR) and Clinical Pregnancy Rate (CPR).

Studies reported patterns of observed Live Birth Rates when comparing women receiving Nmp for luteal support versus those receiving no support in control groups. What remains uncertain is the existence of variability in trial methodology, meaning that the optimal way to use Nmp has not been fully established across all ART protocols.


What is Still Uncertain About the Research for Nmp

The long-term research profile of Nmp is largely determined by its extensive use in Hormone Replacement Therapy (HRT) protocols. For indications like menopausal symptoms and cycle stabilization, the evidence is limited regarding the durability of any measured change beyond intermediate time frames. One primary research limitation frame is that evidence quality varies across studies, particularly for symptom relief indications where findings were mixed and sample sizes were modest in some key trials. The research does not determine whether an individual will respond similarly, and the results apply only to the populations studied.

Key Studies & References

  1. Australian Public Assessment Report for Progesterone (Covers HRT, Cycle Stabilization, and LPS Indications)
  2. Progesterone Vaginal: MedlinePlus Drug Information (Covers FDA/NIH-sanctioned uses and regulatory background)

Frequently Asked Questions (FAQ)

Common questions about Nmp (FAQ)

Q: How does the drug Nmp work inside the body in simple terms?

Nmp's action is described by regulators as supporting hormonal balance. The medicine functions by activating progesterone receptors in the body, which influences how cells communicate. This activity helps regulate factors involved in nervous system signaling and those that help control inflammation.

Q: What happens if a person uses Nmp for several years?

Official warnings specify that the long-term use of Nmp combined with estrogen for Hormone Replacement Therapy (HRT) is associated with an increased risk of serious conditions such as Venous Thromboembolism (VTE), Arterial Thromboembolism (like stroke), and an increased risk of Breast Cancer.

Q: Does Nmp interact with over-the-counter cold and flu medicines?

The official product labeling for Nmp does not explicitly list specific interactions with over-the-counter cold and flu medicines. Due to the lack of explicit data, it is important to ensure your healthcare professional is aware of all products being used.

Q: Are there any known interactions between Nmp and caffeine or alcohol?

Official guidance notes that Nmp may cause side effects like dizziness or drowsiness, and advises against the consumption of alcohol as it may worsen these effects. There is no specific listing for caffeine in the official product information.

Q: What is the risk of interaction between Nmp and common heart medications?

The official product labeling does not explicitly list specific interactions with common heart medications. It is important to ensure your healthcare professional is aware of all prescription drugs being taken.

Q: How is the interaction of Nmp with supplements described in official guidelines?

Official guidelines do not explicitly list specific interactions between Nmp and dietary supplements. Because of this lack of explicit data, it is important to ensure your healthcare professional is aware of all products used, including any supplements.

Q: Why do some patients say they stop using Nmp after a period of time?

Some patients may discontinue use due to common side effects such as headache, dizziness, or breast tenderness that are reported in regulatory documents. Additionally, research indicates that for some uses, the durability of any measured change is limited beyond intermediate time frames, or effectiveness findings are mixed across studies.

Q: How quickly do official documents say Nmp takes full effect?

While the drug concentration in the blood typically peaks rapidly (within 1 to 3 hours), the assessment of full clinical effectiveness in official studies is typically monitored over time, ranging from 12 weeks to 6 months to evaluate symptom changes.

Q: Is hair loss or weight change a noted side effect of Nmp?

Yes, regulatory documents list hair loss or growth of new hair as a potential side effect. Fluid retention (edema) is also listed, which is an effect that may contribute to weight changes.

Q: How long does it usually take to feel the initial effects of Nmp?

According to the official product information, the concentration of the drug in the blood typically peaks within 1 to 3 hours after an oral dose. This peak level indicates the timeframe for maximum concentration in the bloodstream.

Q: Where can I find the official FDA or EMA documents for Nmp?

Official, complete information can be found in the regulatory documents known as the Prescribing Information (PI) or the Summary of Product Characteristics (SmPC). These are available on official websites (like the FDA’s DailyMed or the EMA website) by searching for the active ingredient: Progesterone.

Q: Is Nmp classified as a controlled substance in the U.S. or E.U.?

No, Nmp (Progesterone) is generally classified as a Prescription Only (Rx-only) medication in the U.S. and E.U. countries. Official drug enforcement agencies do not list it as a controlled substance.

Q: What does it mean if Nmp has a 'Black Box Warning'?

The FDA recently initiated the removal of the Boxed Warning (formerly referred to as a 'Black Box Warning') from systemic Hormone Replacement Therapy (HRT) products, which includes this class of medication. The risks associated with this class of medication primarily relate to cardiovascular disease and breast cancer.

Q: If Nmp is discontinued, what is the expectation for effects to wear off?

Pharmacokinetic data reports the elimination half-life for oral Nmp is short, typically ranging from 3 to 90 minutes. This duration relates to the time required for the concentration of the drug to be reduced by half in the circulation.

Q: Are there different brand names for the drug Nmp?

Yes, the active ingredient, micronized progesterone, is available under several brand names in different regions. Examples include Prometrium (oral capsules) and Utrogestan (capsules/suppositories).

Q: Does Nmp affect a person's ability to drive or operate machinery?

Official warnings state that Nmp may cause dizziness or drowsiness. Official guidance recommends exercising caution and suggests patients should not drive or operate machinery until they know how the medicine affects them.

Q: What type of pre-screening tests are typically mentioned before starting Nmp?

Prescribers often recommend baseline laboratory checks to assess factors that may affect treatment. These checks typically include tests for liver and kidney function, lipid profile, and blood sugar, along with age-appropriate cancer screenings like a mammogram.

Q: Is Nmp a relatively new medication?

No. The core active ingredient, Progesterone, was first isolated in 1934. The specific formulation used today, oral micronized progesterone (OMP), has been available for use since 1980.

Q: What does NIH MedlinePlus say about Nmp?

The National Institutes of Health’s MedlinePlus confirms Nmp’s active ingredient is progesterone and lists common side effects like headache and breast tenderness. It specifically warns that the drug may cause dizziness or drowsiness.

Q: Is Nmp suitable for people with pre-existing autoimmune conditions?

The official labeling advises caution. Patients are advised to inform their doctor if they have or have ever had certain conditions, including Lupus (an autoimmune disease) or a history of blood clotting issues, which are a serious risk.

Q: What is the general patient expectation for the duration of Nmp's effect?

The drug is rapidly metabolized, with a short half-life ranging from 3 to 90 minutes in circulation. The administration schedule (e.g., daily) is designed to maintain the therapeutic level of the drug required for its intended purpose.

How should Nmp be stored and disposed of?

Storage and Disposal Requirements for Natural Micronised Progesterone (NMP)

️ Storage Conditions

Natural Micronised Progesterone (NMP) capsules or pessaries must be stored at room temperature, generally not exceeding 30°C. The medicine should not be refrigerated or frozen. To maintain product stability and protect it from moisture, it must be kept in its original package. For safety, keep NMP out of the sight and reach of children.

️ Disposal Instructions

Expired or unused NMP must not be thrown away via wastewater or household waste. Disposal must adhere strictly to local requirements for pharmaceutical waste. Patients should return the product to a pharmacist or designated collection point for safe and environmentally compliant disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nmp found in:

A-Z Index: